GleamWall
中文EN

CGTX COGNITION THERAPEUTICS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1455365 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY42.9%
TTM EPS YoY66.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-48.6%
ROA-40.9%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets15.9%
Debt / equity0.00x
Current ratio6.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.12M$5.10M$6.12M$11.15M$3.77M$11.48M$10.79M$8.15M
SG&A expense$2.25M$2.64M$2.70M$2.52M$2.60M$2.50M$2.99M$2.57M
Operating income-$7.38M-$7.74M-$8.82M-$13.67M-$6.38M-$13.98M-$13.78M-$10.72M
Net income-$4.14M-$3.93M-$4.57M-$3.34M-$4.93M-$6.73M-$8.48M-$7.84M
EBITDA———-$13.66M-$6.36M——-$10.70M
EPS (basic)-0.04-0.04-0.05—-0.06-0.11-0.14—
EPS (diluted)-0.04-0.04-0.05—-0.06-0.11-0.14—
Weighted avg. shares (diluted)95.10M90.62M89.19M—77.95M63.69M61.83M—
Balance sheet
Cash & equivalents$30.76M$34.01M$31.13M$36.81M$39.33M$10.74M$16.43M$25.01M
Current assets$34.24M$38.30M$35.81M$47.99M$42.88M$19.05M$22.87M$29.55M
PP&E, net$76,000$87,000$77,000$93,000$159,000$174,000$190,000$181,000
Total assets$34.80M$38.90M$36.14M$48.39M$43.40M$19.62M$23.50M$30.23M
Current liabilities$5.13M$5.45M$6.05M$13.92M$6.65M$12.36M$10.95M$11.14M
Total liabilities$5.53M$5.87M$6.23M$14.12M$6.87M$12.59M$11.23M$11.48M
Shareholders' equity$29.28M$33.02M$29.91M$34.27M$36.53M$7.03M$12.27M$18.75M
Shares outstanding95.10M95.06M89.35M88.90M88.27M64.96M61.97M59.85M
Cash flow statement
Operating cash flow-$3.26M-$3.05M-$5.54M-$3.44M-$5.65M-$5.62M-$9.88M-$8.38M
Capital expenditure$0——————$1,000
Free cash flow-$3.26M——————-$8.38M
Investing cash flow$0——————-$1,000
Financing cash flow-$28,000$6.61M-$233,000$605,000$33.92M$752,000$1.30M$11.38M
Depreciation & amortization———$14,000$15,000——$27,000
Stock-based compensation$348,000$319,000$330,000$358,000$522,000$621,000$586,000$534,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.